A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin

MicroRNA-29 (miR-29) negatively regulates fibrosis and is downregulated in multiple fibrotic organs and tissues, including in the skin. miR-29 mimics prevent pulmonary fibrosis in mouse models but have not previously been tested in the skin. This study aimed to identify pharmacodynamic biomarkers of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of investigative dermatology Vol. 139; no. 5; p. 1073
Main Authors: Gallant-Behm, Corrie L, Piper, Joseph, Lynch, Joshua M, Seto, Anita G, Hong, Seok Jong, Mustoe, Thomas A, Maari, Catherine, Pestano, Linda A, Dalby, Christina M, Jackson, Aimee L, Rubin, Paul, Marshall, William S
Format: Journal Article
Language:English
Published: United States 01.05.2019
Subjects:
Animals
Biopsy, Needle
Disease Models, Animal
Extracellular Matrix - drug effects
Extracellular Matrix - metabolism
Fibrosis - genetics
Fibrosis - pathology
Gene Expression Regulation
Humans
Immunohistochemistry
Mice
MicroRNAs - genetics
MicroRNAs - pharmacology
Prospective Studies
Skin Diseases - drug therapy
Skin Diseases - genetics
Skin Diseases - pathology
Treatment Outcome
ISSN:1523-1747, 1523-1747
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MicroRNA-29 (miR-29) negatively regulates fibrosis and is downregulated in multiple fibrotic organs and tissues, including in the skin. miR-29 mimics prevent pulmonary fibrosis in mouse models but have not previously been tested in the skin. This study aimed to identify pharmacodynamic biomarkers of miR-29 in mouse skin, to translate those biomarkers across multiple species, and to assess the pharmacodynamic activity of a miR-29b mimic (remlarsen) in a clinical trial. miR-29 biomarkers were selected based on gene function and mRNA expression using quantitative reverse transcriptase polymerase chain reaction. Those biomarkers comprised multiple collagens and other miR-29 direct and indirect targets and were conserved across species; remlarsen regulated their expression in mouse, rat, and rabbit skin wounds and in human skin fibroblasts in culture, while a miR-29 inhibitor reciprocally regulated their expression. Biomarker expression translated to clinical proof-of-mechanism; in a double-blinded, placebo-randomized, within-subject controlled clinical trial of single and multiple ascending doses of remlarsen in normal healthy volunteers, remlarsen repressed collagen expression and the development of fibroplasia in incisional skin wounds. These results suggest that remlarsen may be an effective therapeutic to prevent formation of a fibrotic scar (hypertrophic scar or keloid) or to prevent cutaneous fibrosis, such as scleroderma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1523-1747
1523-1747
DOI:10.1016/j.jid.2018.11.007